Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387203 · ClinicalTrials.gov registry record · Phase 2
Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin
A Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei, sponsored by Mercy Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02387203: Active Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei, sponsored by Mercy Medical Center.
NCT02387203 is a Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei that is active but no longer recruiting, run by Mercy Medical Center. The registered enrollment target is 80 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02387203, a Phase 2 study of Appendiceal Neoplasms and Pseudomyxoma Peritonei, is active but no longer recruiting, sponsored by Mercy Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the impact of antibiotic therapy on the disease progression and overall survival of patients with Pseudomyxoma Peritonei (PMP).
Primary Outcome
Kaplan-Meier survival estimates
Conditions Studied
Interventions
- DRUG PrevPac (Prevacid, Amoxicillin, Clarithromycin)
Study Locations (1)
Maryland
- Mercy Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2015-01 |
| Est. Completion | 2024-12 |
| Phase | Phase 2 |
What the registry record for NCT02387203 still lists
NCT02387203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Appendiceal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PrevPac (Prevacid, Amoxicillin, Clarithromycin) is the first listed.
NCT02387203 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02387203 about?
NCT02387203 is a clinical study titled "Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin". The purpose of this study is to determine the impact of antibiotic therapy on the disease progression and overall survival of patients with Pseudomyxoma Peritonei (PMP).
What is the current status of trial NCT02387203?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2015-01. Estimated completion is 2024-12.
What conditions does trial NCT02387203 study?
This clinical trial studies the following conditions: Appendiceal Neoplasms, Pseudomyxoma Peritonei.
What interventions are being tested in trial NCT02387203?
The interventions under investigation include: PrevPac (Prevacid, Amoxicillin, Clarithromycin) (DRUG).
Who is sponsoring clinical trial NCT02387203?
This trial is sponsored by Mercy Medical Center, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02387203 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Appendiceal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02387203's enrollment target sits among peer trials
80 842nd of 2000 higher than 1,117 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Genetics of Appendix Cancer Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia